Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » News » Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021

  • September 27, 2021

KNOXVILLE, TN, Sept. 21, 2021 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067) was presented at the European Society for Medical Oncology (ESMO) Congress, held online from September 16-21, 2021.

Highlights from the ESMO 2021mNET Presentation:

  • Baseline disease characteristics
    • N = 12 patients: 50% male; median age of 66 years (range 47-79)
    • Primary tumor sites: 7 small bowel (58%), 2 pancreas (17%), 1 caecal (8%), and 2 unknown (17%)
    • NET grades: 5 Grade 1 (42%) and 7 Grade 2 (58%)
    • Refractory to SSA and PRRT; all symptomatic progressive disease
    • Chromogranin A (CgA): median 1,585 μg/L (35-10,370)
  • PV-10 treatment
    • Median number of injected lesions: 1 (1-4)
    • Median number of injection cycles: 1 (1-4); 8 patients (67%) received 1 PV-10 cycle; 4 patients received multiple cycles
  • Safety
    • Injection site pain in 9 of 12 patients (75%)
    • Grade 3 photosensitivity reaction in 1 patient; Grade 3 elevation of hepatic enzymes in 1 patient (resolved by Day 7); carcinoid flare in 2 patients
  • Injected-lesion efficacy (RECIST)
    • 42% partial response (PR) and 42% objective response rate (ORR)
  • Patient-level efficacy (RECIST)
    • 83%a disease control rate (DCR) (10 of 12 patients)
    • Median progression-free survival (PFS): 9.2 months (1.0-41.8)
    • Median overall survival (OS): 22.5 months (5.5-41.8); 6 patients (50%) undergoing response follow-up (data cut-off: April 30, 2021)
  • Immune response
    • Upregulation of NK cells and activated CD4+ T cells observed in peripheral blood collected 7-28 days post-PV-10 injection
  • Biomarkers and quality of life (QOL)
    • CgA stable in 10 patients (83%)
    • Health-related QOL assessments stable or improved at one month in 8 of 11 patients (73%); maintained at 3 months in 6 of 10 patients (60%)

a Typographical error on the poster

A copy of the poster is available on Provectus’ website at https://www.provectusbio.com/media/docs/publications/Phase_1_NET.ESMO-2021.pdf.

Simone Leyden, Chief Executive Officer and Co-Founder of NeuroEndocrine Cancer Australia, and International Neuroendocrine Cancer Alliance (INCA) Research Chair, said “The safety and efficacy data from this Phase 1 clinical trial of single-agent PV-10 present a promising therapy for refractory, symptomatic, neuroendocrine cancer patients with liver metastases, a patient population who are underrepresented when it comes to new medical research and treatment options. We look forward to seeing PV-10’s future use in this refractory setting, and also in Phase 2 combination therapy testing for earlier lines of neuroendocrine cancer treatment.”

Click below to read full article.

Click here

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

5HIAA Urine Collection Instructions for Patients

June 23, 2022

Donor Report 2021/2022

June 21, 2022

Cancer Nurses Society of Australia 24th Annual Congress

June 18, 2022

The Future of Precision Oncology in Nuclear Medicine – Report

June 16, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousAction plan support – short videos wanted!
NextENETS-INCA NET Cancer Day Educational WebinarNext

Related Posts

5HIAA Urine Collection Instructions for Patients

Your doctor may order you to do a 5HIAA 24 hour urine test. Please click below to see the downloadable instruction sheet. Previously there were

Donor Report 2021/2022

It is with heartfelt gratitude that we thank our kind donors who enable us to continue to do what we do. We encourage you to

Cancer Nurses Society of Australia 24th Annual Congress

The 24th Cancer Nurses Society of Australia’s  (CNSA) Annual Congress took place at Brisbane Convention Centre Thursday 16 June to Saturday 18 June 2022. The

The Future of Precision Oncology in Nuclear Medicine – Report

Theranostics refers to a combined therapy and diagnostics approach to patient treatment. It involves the use of a diagnostic drug to first identify and label

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies
Menu
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
Menu
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
Menu
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
Menu
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative